1. What Is the AI in Chronic Disease Management Market?
The AI in Chronic Disease Management Market covers artificial intelligence platforms applied to monitoring, prediction, and intervention in chronic conditions including diabetes, hypertension, heart failure, COPD, and chronic kidney disease. AI chronic disease management encompasses predictive deterioration models, remote patient monitoring AI, automated care plan adjustment engines, and AI-driven patient engagement and adherence tools. Market dynamics reflect chronic disease prevalence growth, healthcare cost concentration in high-risk populations, and value-based care payment models incentivising preventive AI investment.
2. AI in Chronic Disease Management Market Size & Forecast
3. Emerging Technologies
- AI-powered COPD exacerbation prediction tools combining spirometry trend data, symptom logs, and environmental triggers to alert patients and clinicians before acute events are advancing as pulmonary care management tools. Growing adoption at integrated health systems is driven by COPD hospitalisation cost reduction.
- AI chronic kidney disease progression prediction models identifying pre-dialysis patients for nephrology care management are advancing as end-stage renal disease delay tools. Growing adoption at large primary care networks is driven by dialysis cost prevention requirements.
- Multimodal chronic disease AI combining wearable biosensor data, pharmacy claims, and lab results to generate real-time care gap alerts are advancing as population health tools. Growing adoption at value-based care organisations is driven by quality measure performance requirements.
- AI digital therapeutics for diabetes and hypertension delivering personalised behaviour change interventions are advancing as prescription digital health tools. Growing adoption at employer and health plan benefit programmes is driven by cost reduction evidence.
Such innovations are driving change across adjacent industries too. Discover more in our AI In Revenue Cycle Management Market.
4. Key Market Opportunity
The leading opportunity in the AI in Chronic Disease Management Market is the health plan risk stratification and care management opportunity, where payers investing in AI-identified high-risk member programmes create large recurring revenue for AI analytics vendors. Diabetes management AI including CGM-integrated closed-loop systems creates a device and software revenue opportunity as clinical outcomes evidence drives payer coverage expansion. Hospital readmission reduction AI creates a measurable ROI opportunity for health systems subject to CMS readmission penalty programmes. Asia Pacific chronic disease management AI creates geographic expansion opportunity as diabetes and hypertension prevalence growth drives government and employer investment.
5. Top Companies in the AI in Chronic Disease Management Market
The following organisations hold leading positions in the AI in Chronic Disease Management Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Tandem Diabetes Care
- Medtronic (MiniMed, CardioMEMS)
- Livongo (Teladoc)
- Omada Health
- Virta Health
- Wellframe
- HealthSnap
- Nuvation Health
- Cardiogram
- Propeller Health
6. Market Segmentation
The AI in Chronic Disease Management Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Disease | DiabetesCardiovascularRespiratoryKidney DiseaseMulti-Condition |
| By Function | Risk StratificationRemote Monitoring AIAdherence ToolsCare Plan Automation |
| By Setting | Primary CareSpecialist PracticeHealth PlanHospital Transitional Care |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the AI in Chronic Disease Management Market trajectory over the forecast period:
Continuous Glucose Monitor AI Is Enabling Closed-Loop Insulin Delivery Without Manual Dosing.Tandem Diabetes Care's Control-IQ AID system using CGM data and basal insulin AI adjustment, used by 400,000 patients in 2024, achieved HbA1c reduction of 0.8 percentage points in real-world use. Medtronic's MiniMed 780G system with SmartGuard AI demonstrating 75 percent time-in-range in pivotal trial data validated that AI insulin delivery achieves clinical outcomes superior to manual management.
Heart Failure AI Remote Monitoring Is Reducing 30-Day Readmission Rates at Scale.Implantable CardioMEMS device AI combined with Medtronic's Care Management Services, deployed at 1,200 US cardiology centres in 2024, reduced 30-day heart failure readmissions by 38 percent. Medicare readmission penalty programme creating annual USD 528 million in hospital penalties drives cardiology AI investment with clearly measurable financial return for adopting health systems.
AI Risk Stratification Models Are Identifying High-Risk Patients for Intensive Care Management Programmes.Optum's AI complex care model at 12 large employer health plans in 2024 identified the top 3 percent of members accounting for 38 percent of total spend. Health plan care management investment ROI of USD 3 to 6 per USD 1 invested in AI-identified high-risk interventions is creating sustained payer purchasing of AI chronic disease risk tools.
For related market intelligence, see the AI In Hospital Operations Market.
8. Segmental Analysis
By disease, the Diabetes Management segment dominated the AI in Chronic Disease Management Market in 2025. Representing the largest revenue category as CGM-integrated closed-loop insulin systems and digital diabetes management platforms achieve the broadest clinical and commercial scale. The Cardiovascular AI Management segment is the fastest-growing category, advancing as heart failure remote monitoring AI achieves reimbursement pathways and readmission reduction evidence.
By setting, the Health Plan and Payer segment dominated the AI in Chronic Disease Management Market in 2025. Representing the largest setting revenue share. The Primary Care segment is the fastest-growing setting category, advancing as value-based care models expand AI care management tools. The Primary Care growth rate is outpacing the overall AI in Chronic Disease Management Market average, gradually shifting setting revenue composition through 2034.
By function, the Risk Stratification segment dominated the AI in Chronic Disease Management Market in 2025, as payer and ACO investment in identifying high-risk patients for intervention generates the largest AI analytics revenue. Remote Monitoring AI is the fastest-growing function category, driven by wearable sensor and connected device adoption enabling continuous physiological data collection for AI-powered care alerts.
9. Regional Analysis
Regional demand patterns across the AI in Chronic Disease Management Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the AI in Chronic Disease Management Market in 2025, holding 44.7% of the global market. Payers, accountable care organisations, and healthcare providers are deploying AI chronic disease platforms to stratify patient risk, coordinate care interventions, and reduce preventable hospital readmission rates across large patient populations. CMS chronic care management reimbursement codes and increasing value-based care contracts are encouraging healthcare organisations to invest in AI-powered population health and disease management capabilities. Growing patient engagement technology adoption, expanding telehealth infrastructure, and increasing chronic disease prevalence are generating demand for AI-driven care coordination platforms.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 24.02% during the forecast period. The high and rising burden of diabetes, hypertension, and cardiovascular disease across China, India, and Southeast Asia is creating large-scale institutional demand for AI-powered chronic disease management platforms. Government population health initiatives and expanding primary care infrastructure are encouraging health authorities to adopt AI platforms that identify high-risk patients and coordinate preventive interventions. Growing mobile health application adoption, increasing connected medical device penetration, and expanding telehealth infrastructure are enabling AI-powered remote chronic disease monitoring at scale.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The AI in Chronic Disease Management Market was valued at USD 1.56 Bn in 2025 and is projected to reach USD 7.43 Bn by 2034, growing at a CAGR of 18.9% over the 2026–2034 forecast period.
The AI in Chronic Disease Management Market is projected to grow at a CAGR of 18.9% from 2026 to 2034.
North America accounted for the largest share of the AI in Chronic Disease Management Market in 2025, holding 44.7% of the global market.
The leading companies in the AI in Chronic Disease Management Market include Tandem Diabetes Care, Medtronic (MiniMed, CardioMEMS), Livongo (Teladoc), Omada Health, Virta Health, Wellframe, HealthSnap, Nuvation Health, Cardiogram, Propeller Health.
Continuous glucose monitor ai is enabling closed-loop insulin delivery without manual dosing.
By disease, the Diabetes Management segment dominated the AI in Chronic Disease Management Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.